# Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

> **NCT06477536** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Huaota Biopharmaceutical Co., Ltd.** · enrollment: 33 (estimated)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** HB0034

## Key facts

- **NCT ID:** NCT06477536
- **Lead sponsor:** Shanghai Huaota Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-02
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06477536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06477536, "Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06477536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*